Dishman Carbogen Amcis Ltd. (IN:DCAL)
:DCAL
Want to see IN:DCAL full AI Analyst Report?
DCAL Stock Chart & Stats
₹255.15
-₹14.00(-4.80%)
At close: 4:00 PM EST
₹255.15
-₹14.00(-4.80%)
Day’s Range― - ―
52-Week Range₹129.00 - ₹321.15
Previous CloseN/A
Volume578.20K
Average Volume (3M)13.55K
Market Cap
₹27.44B
Enterprise Value₹48.31B
Total Cash (Recent Filing)₹5.32B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.32
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding156,783,100
10 Day Avg. Volume9,637
30 Day Avg. Volume13,551
Financial Highlights & Ratios
PEG Ratio-10.28
Price to Book (P/B)0.58
Price to Sales (P/S)1.25
P/FCF Ratio21.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very High Gross Margin (81.49%)An 81.49% gross margin signals strong production efficiency and pricing power in its API/CDMO operations. High gross margins provide structural buffer versus input cost swings and support reinvestment or margin expansion even if SG&A or one-off items pressure net profit over the next several months.
Strong Free Cash Flow Growth (96.36%)Near-doubling of free cash flow and operating cash well above net income indicate improving cash conversion and liquidity. Robust FCF growth supports capex for capacity, deleveraging, or funding CDMO projects without heavy external financing, strengthening resilience over months ahead.
Manageable Leverage And Strong Equity BaseA conservative capital structure with D/E ~0.41 and equity ratio >58% provides financial flexibility to pursue growth or absorb shocks. This balance-sheet strength reduces refinancing risk and supports investment in capacity or R&D that sustain CDMO competitiveness over the medium term.
Bears Say
Extremely Low Net Profitability And ROEDespite revenue and gross margin recovery, near-zero net margin and negligible ROE signal limited ability to convert top-line into shareholder returns. Persistently low bottom-line profitability constrains retained earnings, dividend capacity, and reduces capital efficiency over coming quarters.
Weak Profit-to-free-cash Conversion (FCF/NI 49.05%)Only about half of reported net income becomes free cash flow, suggesting working capital needs, capex, or noncash items limit cash available for reinvestment. This gap can hamper sustained investment in capacity or reduce buffer against cyclical downturns in CDMO demand.
Revenue Exposed To Project Mix, Utilization And Customer ConcentrationCDMO revenue depends on winning and retaining long-duration programs and on plant utilization. That structural exposure creates cyclicality and concentration risk: loss of a major program or a shift toward lower-margin product mix can materially swing revenue and margins over the medium term.
Dishman Carbogen Amcis Ltd. News
DCAL FAQ
What was Dishman Carbogen Amcis Ltd.’s price range in the past 12 months?
Dishman Carbogen Amcis Ltd. lowest stock price was ₹129.00 and its highest was ₹321.15 in the past 12 months.
What is Dishman Carbogen Amcis Ltd.’s market cap?
Dishman Carbogen Amcis Ltd.’s market cap is ₹27.44B.
When is Dishman Carbogen Amcis Ltd.’s upcoming earnings report date?
Dishman Carbogen Amcis Ltd.’s upcoming earnings report date is May 12, 2026 which is in 13 days.
How were Dishman Carbogen Amcis Ltd.’s earnings last quarter?
Dishman Carbogen Amcis Ltd. released its earnings results on Feb 03, 2026. The company reported -₹0.827 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.827.
Is Dishman Carbogen Amcis Ltd. overvalued?
According to Wall Street analysts Dishman Carbogen Amcis Ltd.’s price is currently Overvalued.
Does Dishman Carbogen Amcis Ltd. pay dividends?
Dishman Carbogen Amcis Ltd. pays a Annually dividend of ₹0.2 which represents an annual dividend yield of N/A. See more information on Dishman Carbogen Amcis Ltd. dividends here
What is Dishman Carbogen Amcis Ltd.’s EPS estimate?
Dishman Carbogen Amcis Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dishman Carbogen Amcis Ltd. have?
Dishman Carbogen Amcis Ltd. has 156,783,100 shares outstanding.
What happened to Dishman Carbogen Amcis Ltd.’s price movement after its last earnings report?
Dishman Carbogen Amcis Ltd. reported an EPS of -₹0.827 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.012%.
Which hedge fund is a major shareholder of Dishman Carbogen Amcis Ltd.?
Currently, no hedge funds are holding shares in IN:DCAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, intermediates, phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D products, fine chemicals, hand and body wash, sanitisers, antiseptics, and various pharmaceutical and cosmetic-related products, as well as generic and highly potent active pharmaceutical ingredients. The company was incorporated in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Jubilant Ingrevia Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―